BioWorld

May 18, 2005

Lexicon, Organon Enter $73M Protein, Antibody Agreement

Signing its fourth major drug discovery alliance, Lexicon Genetics Inc. formed a $72.5 million collaboration with NV Organon to find five drug candidates for inflammatory disease. (BioWorld Today) Read More

NovImmune, Serono Enter Antibody Deal Worth $122M

Amgen, Abgenix Offer Strong Phase II Panitumumab Results

Licensing Deal Gives Spectrum Radiation Adjunct For Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 12, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...